Examining Biomarkers and the Pulmonologist’s Role in Lung Cancer Treatment

Click to Read

In this two-part supplement to CHEST Physician, Brett Bade, MD, (Yale School of Medicine) and Gerard A. Silvestri, MD, MS, FCCP (Medical University of South Carolina) discuss the role that pulmonologists play in lung cancer treatment as well as the clinical relevance of biomarkers.

The content in this supplement is based on proceedings from the Lung Cancer Summit hosted by the American College of Chest Physicians last July. The summit successfully fostered key relationships between clinicians, educators, scientists, advocacy groups, payers, and government entities. Attendees identified opportunities to align efforts toward moving forward a research agenda, supporting the faster-paced adoption of key innovations in care, and improving the accessibility of those innovations to all patient populations. These papers highlight the key clinical elements of the summit. Dr. Silvestri served as Chair of the Summit Steering Committee. 

The supplement includes:

Part 1: Biomarker Use for Pulmonologists: Pulmonary Nodule Management

• Factors that influence the evaluation and management of indeterminate solid nodules
• Summary of key guidelines
• Emergence of biomarkers in clinical trials
   

Part 2: Biomarker Use in Metastatic Non-Small Cell Lung Cancer: What the Pulmonologist Needs to Know

• Expansion of systemic lung cancer treatments in recent years
• Clinical trials demonstrating improved patient outcomes
• Biomarkers being used in targeted therapies

Click to Read

Click to Read

In this two-part supplement to CHEST Physician, Brett Bade, MD, (Yale School of Medicine) and Gerard A. Silvestri, MD, MS, FCCP (Medical University of South Carolina) discuss the role that pulmonologists play in lung cancer treatment as well as the clinical relevance of biomarkers.

The content in this supplement is based on proceedings from the Lung Cancer Summit hosted by the American College of Chest Physicians last July. The summit successfully fostered key relationships between clinicians, educators, scientists, advocacy groups, payers, and government entities. Attendees identified opportunities to align efforts toward moving forward a research agenda, supporting the faster-paced adoption of key innovations in care, and improving the accessibility of those innovations to all patient populations. These papers highlight the key clinical elements of the summit. Dr. Silvestri served as Chair of the Summit Steering Committee. 

The supplement includes:

Part 1: Biomarker Use for Pulmonologists: Pulmonary Nodule Management

• Factors that influence the evaluation and management of indeterminate solid nodules
• Summary of key guidelines
• Emergence of biomarkers in clinical trials
   

Part 2: Biomarker Use in Metastatic Non-Small Cell Lung Cancer: What the Pulmonologist Needs to Know

• Expansion of systemic lung cancer treatments in recent years
• Clinical trials demonstrating improved patient outcomes
• Biomarkers being used in targeted therapies

Click to Read

Click to Read

In this two-part supplement to CHEST Physician, Brett Bade, MD, (Yale School of Medicine) and Gerard A. Silvestri, MD, MS, FCCP (Medical University of South Carolina) discuss the role that pulmonologists play in lung cancer treatment as well as the clinical relevance of biomarkers.

The content in this supplement is based on proceedings from the Lung Cancer Summit hosted by the American College of Chest Physicians last July. The summit successfully fostered key relationships between clinicians, educators, scientists, advocacy groups, payers, and government entities. Attendees identified opportunities to align efforts toward moving forward a research agenda, supporting the faster-paced adoption of key innovations in care, and improving the accessibility of those innovations to all patient populations. These papers highlight the key clinical elements of the summit. Dr. Silvestri served as Chair of the Summit Steering Committee. 

The supplement includes:

Part 1: Biomarker Use for Pulmonologists: Pulmonary Nodule Management

• Factors that influence the evaluation and management of indeterminate solid nodules
• Summary of key guidelines
• Emergence of biomarkers in clinical trials
   

Part 2: Biomarker Use in Metastatic Non-Small Cell Lung Cancer: What the Pulmonologist Needs to Know

• Expansion of systemic lung cancer treatments in recent years
• Clinical trials demonstrating improved patient outcomes
• Biomarkers being used in targeted therapies

Click to Read